Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

748.01 -1.91 (-0.25%)
Official Closing Price Updated: 4:10 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
99 100 Next >
This Analyst Sees Potential Downside In Eli Lilly, Adjusts Model For Acquired IPR&D Charges
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on Eli Lilly with a price target of $885. Eli Lilly's Q2 FY24 earnings report on August 8 will include a pre-tax IPR&D charge of... 
Via Benzinga
7 Top-Quality Stocks to Buy Now: July 2024
With plenty of uncertainties ahead, investors should look for top-quality stocks for the remainder of the year. 
Via InvestorPlace
Americans Are Flying; Airline Stocks Are Not
How the airline industry's focus on capacity and being able to supply more flights means fares are low, even in the face of record demand. 
Via The Motley Fool
Eli Lilly and Co's Options: A Look at What the Big Money is Thinking
Via Benzinga
2 Unstoppable Growth Stocks to Buy and Hold for the Next Decade
These elite companies can help you build lasting wealth. 
Via The Motley Fool
In-Depth Analysis: Eli Lilly and Co Versus Competitors In Pharmaceuticals Industry
Via Benzinga
Positive News is Driving This Cancer Drug Maker’s Stock Higher
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather 
Via MarketBeat
7 Billion-Dollar Stocks That Deserve a Spot in Your Portfolio
Accumulate these billion-dollar stocks before they hit a new high and march towards the trillion dollar status. 
Via InvestorPlace
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
Revenue is climbing at these two drug companies -- and the trend should continue. 
Via The Motley Fool
3 Stocks for Patient Investors Looking to Build Generational Wealth
Investing in generational wealth stocks means holding them for years, preferably decades, to allow them to deliver supercharged returns. 
Via InvestorPlace
2 High-Flying Growth Stocks You Can Buy Right Now Before They Surge Even Higher
Shares are up for very good reasons. 
Via The Motley Fool
2 Incredibly Cheap Growth Stocks to Buy Now
Price is just one factor to consider. 
Via The Motley Fool
Is Eli Lilly a Good Dividend Stock to Buy Now?
A leading anti-obesity treatment plus a new Alzheimer's drug could drive profits through the roof. 
Via The Motley Fool
This 1 Piece of Bad News for Novo Nordisk Is Good News for Eli Lilly Stock
A new study raises important implications regarding the competitive balance between these two companies. 
Via The Motley Fool
The 7 Most Important Stocks to Watch as Q2 Earnings Season Kicks Off
Seven Q2 earnings season stocks are powered by catalysts that could have a major impact on their companies fortunes. 
Via InvestorPlace
3 Powerful Stocks Worthy of Magnificent 7 Status
These Potential Magnificent 7 stocks have quite a run ahead and could challenge the original seven in the second half. 
Via InvestorPlace
MarketBeat Week in Review – 7/8 - 7/12
Stocks took investors on quite a ride this week, with the S&P 500 hitting a new record high, then falling back on Thursday before rallying to end the week 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
Eli Lilly's Alzheimer's Drug Obtains FDA Approval. Here's Why the Stock Isn't Taking Off.
The news likely didn't come as a big surprise to investors. 
Via The Motley Fool
Exposures Product Safety
Did Eli Lilly Just Get a Leg Up on Novo Nordisk?
Eli Lilly's latest milestone sets it apart from its rival Novo Nordisk. 
Via The Motley Fool
SPDR ETF Report For Friday, July 12
In this video, Ira Epstein reviews the day's trading in various SPDR-ETF markets for the trading day that ended, Friday, July 12. 
Via Talk Markets
Topics ETFs
The Next Trillion-Dollar Stocks? 3 Top Contenders to Buy Now
These potential trillion dollar stocks are the next companies poised to join the elite club and drive future market growth. 
Via InvestorPlace
The Weight Loss Market Can Surge To $400B By 2032, And These Stocks Will Rule It
Despite Novo Nordisk's momentum, Eli Lilly seems a better long-term bet. Pfizer could surprise everyone from an undervalued position. 
Via Talk Markets
With Oral Anti-Obesity Candidate Development, Pfizer Seeks Relevant And Competitive Presence - Goldman Sachs
Pfizer has selected its preferred once-daily modified release formulation for danuglipron, an oral GLP-1 receptor agonist, with dose optimization studies planned for late 2024. The study will evaluate... 
Via Benzinga
Novo Nordisk Stock Pops After Weight-Loss Drug Cuts Dementia Risk In Yearlong Study
A yearlong study at the University of Oxford suggests GLP-1 drugs could play a role in protecting brain health. 
Via Investor's Business Daily
Using Ozempic, Zepbound Or Other Weight Loss Drugs? Inform Doctors Before Anesthesia Or Surgery, European Medicines Agency Issues Advisory
EMA advises patients on GLP-1 weight-loss drugs like Wegovy to inform their doctors before surgery due to potential respiratory risks. New warnings to be included in product information to ensure... 
Via Benzinga
Should You Buy Eli Lilly Stock After Another Major Win?
It was a buy even before this development. 
Via The Motley Fool
The 3 Most Undervalued Biotech Stocks to Buy in July 2024
There’s always a strong case for undervalued biotech stocks especially with newer innovation and demand for better treatment. 
Via InvestorPlace
Novo Nordisk's 'Miracle' Weight Loss Drug Ozempic Linked To 48% Lower Risk Of Dementia, Study Finds
Novo Nordisk has found that its diabetes drug, Ozempic, is linked to a significant reduction in the risk of dementia and other cognitive issues. 
Via Benzinga
Eli Lilly, Novo Nordisk Shares Dip As Pfizer Ramps Up Diabetes Drug Competition
Shares of Eli Lilly and Co (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO) are facing declines Thursday, maybe influenced by competitive developments and regulatory updates in the pharmaceutical sector. 
Via Benzinga
First Choice Neurology Pioneering Neurologists Administer the New FDA-Approved Drug Kisunla
JUPITER, Fla. - July 11, 2024 - PRLog -- First Choice Neurology, the largest neurology group in the United States, is set to make medical history next week as Dr. Jennifer Buczyner and Dr. Jeff Gelblum... 
Via PRLog
Exposures Product Safety
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.